Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Lancet Respir Med. 2023 Aug 23;11(11):965–974. doi: 10.1016/S2213-2600(23)00237-0

Figure 1: Summary of the Analysis Plan.

Figure 1:

Latent class analysis (LCA) was used in VALID and EARLI because sufficient number of biomarkers were available across the entire cohort to recapitulate prior work used for discovering molecular phenotypes. In comparison, in PROWESS-SHOCK and VASST protein biomarker availability was insufficient for performing LCA as per our prior procedures. VALID: Validating Acute Lung Injury markers for Diagnosis; EARLI: Early Assessment of Renal and Lung Injury; PROWESS-SHOCK: Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock trial; VASST: Vasopressin and Septic Shock trial; ICAM-1: intercellular adhesion molecule-1, IL-6: interleukin 6; IL-8: interleukin 8; PAI-1: plasminogen activator inhibitor-1; sTNFR-1: soluble tumour necrosis factor receptor-1; CCM = clinical classifier model; PCM = Parsimonious classifier model .